Danielle Lang

Danielle Lang is a Research Academic at the University of Newcastle's School of Medicine and Public Health, leading the Newcastle Evaluation Group (NEG) specializing in health technology assessment. With over 20 years of experience, she has contributed to more than 200 confidential HTA reports across cardiovascular disease, diabetes, and mental health domains. Her work influences healthcare decision-making through organizations such as the Pharmaceutical Benefits Advisory Committee (PBAC) and Medicare Services Advisory Committee (MSAC).

Education:

• Post Graduate Diploma in Health Economics and Eval, Monash University
• Bachelor of Mathematics/Bachelor of Economics, University of Newcastle

Her research focuses on health economics, economic evaluation, pharmacoeconomics, and health technology assessment, particularly in cost-consequence analysis and economic modeling of healthcare interventions. Research domains include pharmaceutical evaluation, maternal health economics, surgical trial economics, and chronic disease management.

Publication trends demonstrate consistent focus on economic evaluation methodologies, healthcare resource allocation, and technology assessment. Recent work explores surgical trial participation economics while earlier publications established pharmacoeconomic evaluation frameworks.

Grants & Funding: Since 1998, Dr. Lang has secured over $28 million in research funding primarily from the Australian Department of Health and Aged Care. Major grants include:

• The Provision Of External Evaluation Of PBAC Submissions ($5,992,528)
• Provision of external evaluation of PBAC submissions ($8,204,899)
• External Evaluation of PBAC Submissions ($5,826,326)

She leads the multidisciplinary Newcastle Evaluation Group (NEG), Australia's longest-standing university-based HTA research group, which evaluates clinical benefit, safety, and cost-effectiveness of healthcare interventions.